The state of the art—psoriatic arthritis outcome assessment in clinical trials and daily practice

Julia Day; Anna Antony; William Tillett; Laura C Coates

doi:10.1016/S2665-9913(21)00349-0

The state of the art—psoriatic arthritis outcome assessment in clinical trials and daily practice

Julia Day, Anna Antony, William Tillett, Laura C Coates

Research output: Contribution to journal › Review article › peer-review

5 Citations (SciVal)

193 Downloads (Pure)

Abstract

Psoriatic arthritis is a heterogeneous condition with substantial challenges in optimising outcome measures for both clinical trials and daily practice. As with other inflammatory arthritides, there is no gold standard instrument for measuring disease activity or impact, both of which are key to evaluate therapeutic approaches in trials and monitor disease in daily practice. A wide range of domains have been highlighted in the Outcome Measures in Rheumatology (OMERACT) core domain set for psoriatic arthritis; reflecting the disease involvement in multiple tissues (joints, tendons, skin, and spine) and the heterogenous impact of the disease on individuals. This Review summarises the current evidence around outcome measure selection, considering factors such as unidimensional versus multidimensional outcomes, continuous versus binary measures, and the feasibility of these approaches in trials compared with clinical practice.

Original language	English
Pages (from-to)	e220-e228
Number of pages	9
Journal	The Lancet Rheumatology
Volume	4
Issue number	3
Early online date	20 Jan 2022
DOIs	https://doi.org/10.1016/S2665-9913(21)00349-0
Publication status	Published - 31 Mar 2022

Bibliographical note

Funding Information:
We declare no competing interests related to this work. Outside of this work, JD declares no competing interests. AA declares support for attending meetings and travel from Roche and Janssen. WT has received grants and research support from AbbVie, Amgen, Celgene, Eli Lilly, Janssen Novartis, and UCB; consulting fees, honoraria for lectures, support for attending meetings and travel, and participation in advisory boards from AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB.. LCC has received grants and research support from AbbVie, Amgen, Celgene, Eli Lilly, Novartis and Pfizer; received payment for lectures from AbbVie, Amgen, Biogen, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Medac, Novartis, Pfizer and UCB; support for attending meetings and travel from Janssen; participation in advisory boards for AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Gilead, Galapagos, Janssen, Novartis, Pfizer and UCB; and is chair of the British Psoriatic Arthritis consortium.

Funding Information:
LCC is funded by a National Institute for Health Research Clinician Scientist award. The work was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the National Health Service, the NIHR or the Department of Health.

Publisher Copyright:
© 2022 Elsevier Ltd

Funding

LCC is funded by a National Institute for Health Research Clinician Scientist award. The work was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the National Health Service, the NIHR or the Department of Health.

ASJC Scopus subject areas

Rheumatology
Immunology and Allergy
Immunology

Access to Document

10.1016/S2665-9913(21)00349-0

Lancet_PsA_review_12Oct2021.PDFAccepted author manuscript, 507 KBLicence: CC BY-NC-ND

Cite this

@article{67aeca85a986401784aa0106c266628a,

title = "The state of the art—psoriatic arthritis outcome assessment in clinical trials and daily practice",

abstract = "Psoriatic arthritis is a heterogeneous condition with substantial challenges in optimising outcome measures for both clinical trials and daily practice. As with other inflammatory arthritides, there is no gold standard instrument for measuring disease activity or impact, both of which are key to evaluate therapeutic approaches in trials and monitor disease in daily practice. A wide range of domains have been highlighted in the Outcome Measures in Rheumatology (OMERACT) core domain set for psoriatic arthritis; reflecting the disease involvement in multiple tissues (joints, tendons, skin, and spine) and the heterogenous impact of the disease on individuals. This Review summarises the current evidence around outcome measure selection, considering factors such as unidimensional versus multidimensional outcomes, continuous versus binary measures, and the feasibility of these approaches in trials compared with clinical practice.",

author = "Julia Day and Anna Antony and William Tillett and Coates, {Laura C}",

note = "Funding Information: We declare no competing interests related to this work. Outside of this work, JD declares no competing interests. AA declares support for attending meetings and travel from Roche and Janssen. WT has received grants and research support from AbbVie, Amgen, Celgene, Eli Lilly, Janssen Novartis, and UCB; consulting fees, honoraria for lectures, support for attending meetings and travel, and participation in advisory boards from AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB.. LCC has received grants and research support from AbbVie, Amgen, Celgene, Eli Lilly, Novartis and Pfizer; received payment for lectures from AbbVie, Amgen, Biogen, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Medac, Novartis, Pfizer and UCB; support for attending meetings and travel from Janssen; participation in advisory boards for AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Gilead, Galapagos, Janssen, Novartis, Pfizer and UCB; and is chair of the British Psoriatic Arthritis consortium. Funding Information: LCC is funded by a National Institute for Health Research Clinician Scientist award. The work was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the National Health Service, the NIHR or the Department of Health. Publisher Copyright: {\textcopyright} 2022 Elsevier Ltd",

year = "2022",

month = mar,

day = "31",

doi = "10.1016/S2665-9913(21)00349-0",

language = "English",

volume = "4",

pages = "e220--e228",

journal = "The Lancet Rheumatology",

issn = "2665-9913",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - The state of the art—psoriatic arthritis outcome assessment in clinical trials and daily practice

AU - Day, Julia

AU - Antony, Anna

AU - Tillett, William

AU - Coates, Laura C

N1 - Funding Information: We declare no competing interests related to this work. Outside of this work, JD declares no competing interests. AA declares support for attending meetings and travel from Roche and Janssen. WT has received grants and research support from AbbVie, Amgen, Celgene, Eli Lilly, Janssen Novartis, and UCB; consulting fees, honoraria for lectures, support for attending meetings and travel, and participation in advisory boards from AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB.. LCC has received grants and research support from AbbVie, Amgen, Celgene, Eli Lilly, Novartis and Pfizer; received payment for lectures from AbbVie, Amgen, Biogen, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Medac, Novartis, Pfizer and UCB; support for attending meetings and travel from Janssen; participation in advisory boards for AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Gilead, Galapagos, Janssen, Novartis, Pfizer and UCB; and is chair of the British Psoriatic Arthritis consortium. Funding Information: LCC is funded by a National Institute for Health Research Clinician Scientist award. The work was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the National Health Service, the NIHR or the Department of Health. Publisher Copyright: © 2022 Elsevier Ltd

PY - 2022/3/31

Y1 - 2022/3/31

N2 - Psoriatic arthritis is a heterogeneous condition with substantial challenges in optimising outcome measures for both clinical trials and daily practice. As with other inflammatory arthritides, there is no gold standard instrument for measuring disease activity or impact, both of which are key to evaluate therapeutic approaches in trials and monitor disease in daily practice. A wide range of domains have been highlighted in the Outcome Measures in Rheumatology (OMERACT) core domain set for psoriatic arthritis; reflecting the disease involvement in multiple tissues (joints, tendons, skin, and spine) and the heterogenous impact of the disease on individuals. This Review summarises the current evidence around outcome measure selection, considering factors such as unidimensional versus multidimensional outcomes, continuous versus binary measures, and the feasibility of these approaches in trials compared with clinical practice.

AB - Psoriatic arthritis is a heterogeneous condition with substantial challenges in optimising outcome measures for both clinical trials and daily practice. As with other inflammatory arthritides, there is no gold standard instrument for measuring disease activity or impact, both of which are key to evaluate therapeutic approaches in trials and monitor disease in daily practice. A wide range of domains have been highlighted in the Outcome Measures in Rheumatology (OMERACT) core domain set for psoriatic arthritis; reflecting the disease involvement in multiple tissues (joints, tendons, skin, and spine) and the heterogenous impact of the disease on individuals. This Review summarises the current evidence around outcome measure selection, considering factors such as unidimensional versus multidimensional outcomes, continuous versus binary measures, and the feasibility of these approaches in trials compared with clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=85124008815&partnerID=8YFLogxK

U2 - 10.1016/S2665-9913(21)00349-0

DO - 10.1016/S2665-9913(21)00349-0

M3 - Review article

SN - 2665-9913

VL - 4

SP - e220-e228

JO - The Lancet Rheumatology

JF - The Lancet Rheumatology

IS - 3

ER -

The state of the art—psoriatic arthritis outcome assessment in clinical trials and daily practice

Abstract

Bibliographical note

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Outcome Measures for Randomised Controlled Trials in Psoriatic Arthritis

Cite this

The state of the art—psoriatic arthritis outcome assessment in clinical trials and daily practice

Abstract

Bibliographical note

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Projects

Outcome Measures for Randomised Controlled Trials in Psoriatic Arthritis

Cite this